Weill David, an insider at Transmedics Group Inc (TMDX), purchased 17,134 shares of the company on December 2, 2025, at a price of $14.20 per share, totaling approximately $243,000. This transaction increases David's holdings to the same number of shares.
Transmedics Group operates as a commercial stage medical technology firm specializing in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. The company, headquartered in Andover, Massachusetts, has a market capitalization of $4.2 billion and a P/E ratio of 46.19, with an EPS of 2.29.
Upcoming earnings reports are scheduled for May 6, 2026, with an estimated EPS of $0.70 and revenue of $174.5 million, followed by another report on July 28, 2026, with an estimated EPS of $0.85 and revenue of $189.2 million.
Insider transactions such as this one provide insight into how executives view their company's stock. However, investors should consider these actions alongside broader market factors and other insider activities to form a comprehensive view.